Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

The scrubbing of clinical trial-related pages is notable because of how it could affect the ways researchers both inside and ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

Novo Nordisk has been one of the chief beneficiaries ... along with other potential health benefits. That drove Novo’s U.S.-listed shares to a record high of $148.15 this past June, up more ...